# Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

> **NCT03455504** · PHASE2 · UNKNOWN · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 124 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03455504
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-26
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2024-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455504, "Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03455504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*